A scan of ClinicalTrials.gov for what's been moving in March 2026. All trial numbers link directly to the registry entry.
## Cybin's CYB003 — Phase 3 for Major Depression
The furthest-along compound right now is Cybin's CYB003, a deuterated psilocin analog. Their [Phase 3 trial (NCT06564818)](https://clinicaltrials.gov/study/NCT06564818) has been recruiting since December 2024, targeting 220 participants with major depressive disorder. Primary completion is estimated for August 2026. The design is randomized, double-blind, placebo-controlled.
## MDMA Training for Therapists — Mount Sinai
An unusual [Phase 1 study (NCT07102576)](https://clinicaltrials.gov/study/NCT07102576) led by Rachel Yehuda at Mount Sinai is giving MDMA to mental health providers who are training to become MDMA-assisted therapists — so providers experience the drug themselves as part of their training. Open-label, currently recruiting.
## Psilocybin for Alcohol Use Disorder — Brigham and Women's
Brigham and Women's Hospital has registered a [Phase 2 trial (NCT07296094)](https://clinicaltrials.gov/study/NCT07296094) testing psilocybin-assisted psychotherapy for severe alcohol use disorder. 36 participants. Not yet recruiting.
## Psilocybin for OCD — CAMH
The Centre for Addiction and Mental Health in Toronto is running a [Phase 1 feasibility study (NCT06299319)](https://clinicaltrials.gov/study/NCT06299319) on psilocybin-assisted therapy for OCD. Currently recruiting.
## Psilocybin and Fluoxetine — Brazil
A [Phase 1/2 trial (NCT06898606)](https://clinicaltrials.gov/study/NCT06898606) out of the Federal University of Latin American Integration is testing psilocybin with or without fluoxetine for depression. The drug interaction question — SSRIs potentially blunting psilocybin's effects — is a genuine clinical issue given how many patients are already on antidepressants. Recruiting.